US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.30 against a street estimate of 0.14 — a beat of 114.3%.
Analysts rate BioCryst Pharmaceuticals Inc a buy (11 buy, 1 hold, 0 sell out of 12) with an average price target of $20.64.
CONFIDENT BioCryst delivered strong Q2 with ORLADEYO growing 10% YoY, pediatric launch off to robust start (47 Rx vs. full-year expectations), and navenibart enrollment complete ahead of schedule. Cost cuts underway post-Birmingham closure. Q2 2026 Navenibart EU rights licensed to Neopharmed Gentili. Former European ORLADEYO business divested. U.S. focus for ORLADEYO growth. Analysts pressed on ORLADEYO volume breakdown (Charlie clarified 50/50 split), Netherton efficacy bar (Sandeep: first targeted KLK5 therapy; any relief major advance), and pediatric paid rates (Charlie: expect 80%+; early signs strong). Management confidence throughout; no material walk-backs. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.86% |
| RA Capital Management, LLC | 6.19% |
| Deerfield Management Co | 5.88% |
| State Street Corp | 4.78% |
| Vanguard Portfolio Management, LLC | 4.40% |
| Vanguard Capital Management, LLC | 4.36% |
| TCG Crossover Management, LLC | 4.31% |
| HHG PLC | 3.49% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 BIOCRYST PHARMACEUTICALS, INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and equivalents: $154.972 million (June 30, 2026) vs $89.736 million ( | 2026-08-05 |
| Results announced · Q3 2026 BIOCRYST PHARMACEUTICALS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenue: $218.3 million (+34% year-over-year; +45% excluding Eur | 2026-08-05 |
| Reg FD disclosure · Q2 2026 BIOCRYST PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Report Date: June 25, 2026 (Board approval); June 29, 2026 (public announcement | 2026-06-29 |
| Board / officer change · Q2 2026 BIOCRYST PHARMACEUTICALS, INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 11, 2026 • 7,000,000 additional shares approved for is | 2026-06-12 |
| Quarterly report · Q1 2026 BIOCRYST PHARMACEUTICALS, INC. — Q1 2026 SUMMARY HEADLINE NUMBERS • Cash position: $171.6 million in cash and cash equivalents as of March 31, 2026 | 2026-05-06 |
| Results announced · Q2 2026 BIOCRYST PHARMACEUTICALS Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q1 2026 ORLADEYO net revenue: $148.3 million (+11% year-over-year; +21% exclud | 2026-05-06 |
| Proxy statement · Q2 2026 BIOCRYST PHARMACEUTICALS, INC. – PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of Three Directors – Voting to | 2026-04-23 |
| Annual report FY2025 BIOCRYST PHARMACEUTICALS, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market Capitalization: $1.86 billion (as of June 30, 2025, bas | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| Maintained ORLADEYO revenue guidance, increased total revenue guidance for 2026 BioCryst Pharmaceuticals reported strong Q2 2026 results with total revenue of $218.3 million (up 34% year-over-year) and ORLADEYO net revenue of $158.2 million. The company achieved operati | 2026-08-05 |
| 2026 non-GAAP operating expense guidance improved; revenue guidance reaffirmed BioCryst Pharmaceuticals announced a strategic shift to focus on external innovation rather than internal drug discovery. The company will close its Birmingham, Alabama research facility by | 2026-06-29 |
| Licensing agreement for European navenibart rights to Neopharmed Gentili BioCryst Pharmaceuticals reported strong Q1 2026 results with ORLADEYO (its main drug for hereditary angioedema) generating $148.3 million in revenue, up 11% year-over-year. More importantly | 2026-05-06 |
| European licensing agreement for navenibart in hereditary angioedema BioCryst Pharmaceuticals signed a licensing deal with an Irish affiliate of Neopharmed Gentili to commercialize navenibart (an experimental HAE treatment) in Europe. BioCryst will receive $7 | 2026-05-04 |
| Completed acquisition of Astria Therapeutics to expand HAE portfolio BioCryst Pharmaceuticals achieved a major milestone in 2025 by reaching full-year profitability for the first time in company history. Their flagship drug ORLADEYO generated $601.8 million i | 2026-02-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BioCryst Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.